These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 33753834)
1. TMAO: a potential mediator of clopidogrel resistance. Ma R; Fu W; Zhang J; Hu X; Yang J; Jiang H Sci Rep; 2021 Mar; 11(1):6580. PubMed ID: 33753834 [TBL] [Abstract][Full Text] [Related]
2. Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention. Ahn SG; Lee SH; Sung JK; Kim JY; Yoon J Platelets; 2011; 22(4):305-7. PubMed ID: 21480769 [No Abstract] [Full Text] [Related]
3. Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel. Labarthe B; Babin J; Bryckaert M; Théroux P; Bonnefoy A Br J Pharmacol; 2012 May; 166(1):221-31. PubMed ID: 21950486 [TBL] [Abstract][Full Text] [Related]
4. Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y Brambilla M; Becchetti A; Rovati GE; Cosentino N; Conti M; Canzano P; Giesen PLA; Loffreda A; Bonomi A; Cattaneo M; De Candia E; Podda GM; Trabattoni D; Werba PJ; Campodonico J; Pinna C; Marenzi G; Tremoli E; Camera M Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):2042-2057. PubMed ID: 37589138 [TBL] [Abstract][Full Text] [Related]
5. A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y Li X; Liu P; Xu Z; Sun D; Gu J; Miao Y; Zhang J; Cao X Cardiovasc Drugs Ther; 2020 Feb; 34(1):15-23. PubMed ID: 32062793 [TBL] [Abstract][Full Text] [Related]
6. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. Chirumamilla AP; Maehara A; Mintz GS; Mehran R; Kanwal S; Weisz G; Hassanin A; Hakim D; Guo N; Baber U; Pyo R; Moses JW; Fahy M; Kovacic JC; Dangas GD JACC Cardiovasc Imaging; 2012 May; 5(5):540-9. PubMed ID: 22595163 [TBL] [Abstract][Full Text] [Related]
7. [Antiplatelet therapy in coronary heart disease. Some problems and achivements]. Gratsianskiĭ NA Kardiologiia; 2010; 50(6):4-21. PubMed ID: 20659022 [TBL] [Abstract][Full Text] [Related]
8. Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease. Perneby C; Wallén NH; Hofman-Bang C; Tornvall P; Ivert T; Li N; Hjemdahl P Thromb Haemost; 2007 Dec; 98(6):1316-22. PubMed ID: 18064330 [TBL] [Abstract][Full Text] [Related]
9. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036 [TBL] [Abstract][Full Text] [Related]
10. The effect of smoking on residual platelet reactivity to clopidogrel: a systematic review and meta-analysis. Liu Z; Xiang Q; Mu G; Xie Q; Zhou S; Wang Z; Chen S; Hu K; Gong Y; Jiang J; Cui Y Platelets; 2020; 31(1):3-14. PubMed ID: 30744477 [TBL] [Abstract][Full Text] [Related]
11. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease. Nishi T; Ariyoshi N; Nakayama T; Fujimoto Y; Sugimoto K; Takahara M; Wakabayashi S; Koshizaka M; Hanaoka H; Kobayashi Y Circ J; 2015; 79(11):2439-44. PubMed ID: 26310876 [TBL] [Abstract][Full Text] [Related]
12. The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study. Jakubowski JA; Angiolillo DJ; Zhou C; Small DS; Moser BA; Ten Berg JM; Brown PB; James S; Winters KJ; Erlinge D Thromb Res; 2014 Sep; 134(3):552-7. PubMed ID: 25022828 [TBL] [Abstract][Full Text] [Related]